An unexpected effect of glucocorticoids on stimulation of c-fms proto-oncogene expression in choriocarcinoma cells that express little glucocorticoid receptor

被引:9
作者
Chambers, SK
Ivins, CM
Kacinski, BM
Hochberg, RB
机构
[1] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
关键词
glucocorticoid; glucocorticoid receptor; c-fms proto-oncogene; choriocarcinoma;
D O I
10.1016/j.ajog.2004.01.021
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to determine the mechanism by which glucocorticoids stimulate c-fms proto-oncogene expression in JAR choriocarcinoma cells, which are reported to lack the glucocorticoid receptor. Study design: Glucocorticoid action on c-finis was tested with the use of ligand binding assays, Northern and Western blotting, immunohistochemistry, quantitative reverse transcriptase-polymerase chain reaction, and nuclear run-off experiments. Results: Dexamethasone stimulated c-fms (EC50 = 1 nmol/L) in JAR cells in a specific manner. Both RU 486 and actinomycin D inhibited dexamethasone stimulation, which suggests receptor-mediated and transcriptionally regulated actions. Neither cytosol or whole cell binding assays nor immunohistochemistry detected glucocorticoid receptor in JAR cells. However, Southern blot analysis of reverse transcriptase-polymerase chain reaction products revealed levels of glucocorticoid receptor messenger RNA in JAR cells that were approximately 100-fold lower than in HeLa control cells. In all but 1 clone among several JAR clones that were tested, there was concordance between presence or absence of glucocorticoid receptor messenger RNA and glucocorticoid sensitivity. Conclusion: Some JAR cells contain low levels of glucocorticoid receptor, which mediate dexamethasone stimulation of c-fms expression. Such sensitivity to circulating glucocorticoids confers a survival advantage to these cells by stimulating the c-fms-related invasive behavior so characteristic of choriocarcinomas. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:974 / 983
页数:10
相关论文
共 32 条
[1]   IDENTIFICATION OF THE ACTIVATION-LABILE GENE - A SINGLE-POINT MUTATION IN THE HUMAN GLUCOCORTICOID RECEPTOR PRESENTS AS 2 DISTINCT RECEPTOR PHENOTYPES [J].
ASHRAF, J ;
THOMPSON, EB .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (05) :631-642
[2]  
AZODI M, 1999, P INT GYNECOL CANC S
[3]   Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids [J].
Bamberger, CM ;
Schulte, HM ;
Chrousos, GP .
ENDOCRINE REVIEWS, 1996, 17 (03) :245-261
[4]  
CHAMBERS SK, 1995, CANCER RES, V55, P1578
[5]  
Chambers SK, 1997, CLIN CANCER RES, V3, P999
[6]  
CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328
[7]   POSTTRANSCRIPTIONAL REGULATION OF C-FMS PROTOONCOGENE EXPRESSION BY DEXAMETHASONE AND OF CSF-1 IN HUMAN BREAST CARCINOMAS IN-VITRO [J].
CHAMBERS, SK ;
WANG, YX ;
GILMOREHEBERT, M ;
KACINSKI, BM .
STEROIDS, 1994, 59 (09) :514-522
[8]   NOVEL ANTIPEPTIDE ANTIBODIES TO THE HUMAN GLUCOCORTICOID RECEPTOR - RECOGNITION OF MULTIPLE RECEPTOR FORMS INVITRO AND DISTINCT LOCALIZATION OF CYTOPLASMIC AND NUCLEAR RECEPTORS [J].
CIDLOWSKI, JA ;
BELLINGHAM, DL ;
POWELLOLIVER, FE ;
LUBAHN, DB ;
SAR, M .
MOLECULAR ENDOCRINOLOGY, 1990, 4 (10) :1427-1437
[9]  
Fulop V, 1998, J REPROD MED, V43, P101
[10]  
HOCHBERG A, 1992, CANCER RES, V52, P3713